(MedPage Today) — WASHINGTON — Treatment with the investigational GLP-1/glucagon dual receptor agonist pemvidutide led to resolution of metabolic dysfunction-associated steatohepatitis (MASH) without worsening of fibrosis, but did not improve…
Source link : https://www.medpagetoday.com/meetingcoverage/aasld/118438
Author :
Publish date : 2025-11-11 15:03:00
Copyright for syndicated content belongs to the linked Source.
